Phenotypic Expression and Outcomes in Patients with the p.Arg301Gln GLA Variant in Anderson–Fabry Disease
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25084299 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Rocío Blanco und 19 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, Hospital Universitario Son Llatzer, 07198 Palma de Mallorca, Spain. Hauptthemen laut MEDLINE: Fabry Disease, alpha-Galactosidase, Phenotype. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The p.Arg301Gln variant in the α -galactosidase A gene (GLA) has been poorly described in the literature. The few reports show controversial information, with both classical and nonclassical Anderson–Fabry Disease (AFD) presentation patterns. The aim of this study was to analyze the penetrance, clinical phenotype, and biochemical profile of an international cohort of patients carrying the p.Arg301Gln genetic variant in the GLA gene. This was an observational, international, and retrospective cohort case series study of patients carrying the p.Arg301Gln variant in the GLA gene associated with AFD disease. Forty-nine p.Arg301Gln GLA carriers, 41% male, were analyzed. The penetrance was 63% in the entire cohort and 1.5 times higher in men. The mean age of symptoms onset was 41 years; compared to women, men presented symptoms earlier and with a shorter delay to diagnosis. The typical clinical triad—cornea verticillate, neuropathic pain, and angiokeratomas—affected only 20% of the cohort, with no differences between genders. During follow-up, almost 20% of the patients presented some type of nonfatal cardiovascular and renal event (stroke, need for dialysis, heart failure, and arrhythmias requiring intracardiac devices), predominantly affecting men. Residual levels were the most common finding of α-GAL A enzyme activity, only a few women had a normal level; a small proportion of men had undetectable levels. The incidence of combined outcomes including all causes of death was 33%, and the cumulative incidence of all-cause mortality was 9% at the follow-up. Patients carrying the p.Arg301Gln GLA variant have a high penetrance, with predominantly cardiorenal involvement and clinical onset of the disease in middle age. Only a small proportion showed the classic clinical presentation of AFD. As in other X-linked diseases, males were more affected by severe cardiovascular and renal events. This genotype–phenotype correlation could be useful from a practical clinical point of view and for future decision making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiology Department, Hospital Universitario Son Llatzer, 07198 Palma de Mallorca, Spain.
- Cardiology Department, Italian Hospital of Buenos Aires, Buenos Aires C1199ABB, Argentina.
- Cardiology Department, Hospital Universitario Son Espases, 07120 Palma de Mallorca, Spain.
- Department of Internal Medicine, Clinical University Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain.
- Department of Endocrinology and Clinical Nutrition, University Hospital Zurich, 8091 Zurich, Switzerland.
- Division of Internal Medicine, Psychiatric University Hospital Zurich, 8008 Zurich, Switzerland.
ORCID-Profile: Álvaro Hermida-Ameijeiras, Israa Mahmoud Sanad Abdullah, Kolja Lau, Amparo Martínez-Monzonís, Albina Nowak, Peter Nordbeck, Emiliano Rossi, Fiama Caimi-Martínez, Virginia Ruiz-Pizarro, Laura Torres-Juan, Damian Heine-Suñer, Tomás Ripoll-Vera
Zitieren
APA
Blanco, R., Rico-Ramírez, Y., Hermida-Ameijeiras, Á., Abdullah, I. M. S., Lau, K., Alvarez-Rubio, J., Fortuny, E., Martínez-Monzonís, A., Nowak, A., Nordbeck, P., Veras-Burgos, C., Pons-Llinares, J., Rossi, E., Caimi-Martínez, F., Bosch-Rovira, T., Alamar-Cervera, M., Ruiz-Pizarro, V., Torres-Juan, L., Heine-Suñer, D., & Ripoll-Vera, T. (2024). Phenotypic Expression and Outcomes in Patients with the p.Arg301Gln GLA Variant in Anderson–Fabry Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25084299
Vancouver
Blanco R, Rico-Ramírez Y, Hermida-Ameijeiras Á, Abdullah IMS, Lau K, Alvarez-Rubio J, et al. Phenotypic Expression and Outcomes in Patients with the p.Arg301Gln GLA Variant in Anderson–Fabry Disease. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25084299
BibTeX
@article{Blanco2024,
author = {Blanco, Rocío and Rico-Ramírez, Yolanda and Hermida-Ameijeiras, Álvaro and Abdullah, Israa Mahmoud Sanad and Lau, Kolja and Alvarez-Rubio, Jorge and Fortuny, Elena and Martínez-Monzonís, Amparo and Nowak, Albina and Nordbeck, Peter and Veras-Burgos, Carlos and Pons-Llinares, Jaume and Rossi, Emiliano and Caimi-Martínez, Fiama and Bosch-Rovira, Teresa and Alamar-Cervera, Marta and Ruiz-Pizarro, Virginia and Torres-Juan, Laura and Heine-Suñer, Damian and Ripoll-Vera, Tomás},
title = {Phenotypic Expression and Outcomes in Patients with the p.Arg301Gln GLA Variant in Anderson–Fabry Disease},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25084299}
}
EUVIMED